<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872858</url>
  </required_header>
  <id_info>
    <org_study_id>jianhuifu2013</org_study_id>
    <nct_id>NCT01872858</nct_id>
    <nct_alias>NCT01862575</nct_alias>
  </id_info>
  <brief_title>Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <brief_summary>
    <textblock>
      Patients of vascular cognitive impairment-no dementia (VCIND) in one group is prescribed
      cilostazol,in the other group is prescribed aspirin. Evaluate both of them in cognitive
      function, MRI and other sides at given time. The investigators hypothesize that cilostazol is
      more efficient and safer than aspirin in patients with VCIND.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in cognitive function</measure>
    <time_frame>baseline, 3month, 6month, 1year, and 2year</time_frame>
    <description>scores in Montreal Cognitive Assessment，Mini-Mental Status Examination, Clinal Dementia Rating，trail making test, similarity test, Stroop test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Incident cerebral vascular event</measure>
    <time_frame>3month, 6month, 1year and 2year</time_frame>
    <description>including cerebral infarct, cerebral hemorrhage, transient ischemic attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of peripheral inflammatory markers level</measure>
    <time_frame>baseline, 2year</time_frame>
    <description>intercellular adhesion molecules(ICAM), thrombomodulin, tissue factor(TF), tissue factor plasma inhibitor，TFPI, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progression of cerebral white matter lesion and lacunar infarction</measure>
    <time_frame>baseline, 3month, 6month, 1year and 2year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in MRI-diffused tension image(DTI)</measure>
    <time_frame>baseline, 2year</time_frame>
    <description>cerebral volume , lacune infarct, white matter lesion, micro-bleed, apparent diffusion coefficient(ADC) .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin, 100mg, Q.D, p.o, 2yr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol, 100mg, B.I.D, p.o, 2yr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin, 100mg, Q.D, p.o, 2yr</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>cilostazol, 100mg, B.I.D, p.o, 2yr</description>
    <arm_group_label>Cilostazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 50-80, both gender；

          2. Small vessel disease and associated cognitive impairment, diagnosed as VCIND；

          3. Non-specific subjective symptoms (dizziness, somnolence, numbness in limbs) are
             acceptable.

          4. Normal hepatic and renal function.

          5. With good compliance.

        Exclusion Criteria:

          1. Aged above 80 or less than 50.

          2. Dementia.

          3. Cerebral infarction(&gt;2cm).

          4. Major vascular lesion. (stenosis&gt;50%).

          5. Cardiac cerebral infarction.

          6. Intracerebral Hemorrhage.

          7. Clinical manifestations cannot attribute to small vessel disease.

          8. Major depression or dysfunction in speech, visual ability, hearing or aphasia that
             would interfere with the cognitive assessment.

          9. Severe systematic organic impairment(cardiac, hepatic, renal dysfunction).

         10. Thrombocytopenic Purpura.

         11. History of hemorrhage in digestive system or surgery in past 3 months.

         12. Previously on cilostazol treatment for more than 3 month.

         13. Allergic to aspirin or cilostazol.

         14. Enrolled in other clinical trials in past 3 months.

         15. Lack of informed consent or compliance.

         16. Contraindications for MRI scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Neurology, Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Tang</last_name>
      <phone>+8618818210880</phone>
      <email>tan11711@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jianhui Fu</investigator_full_name>
    <investigator_title>Department of Neurology, Huashan Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

